Serum markers of intrahepatic cholangiocarcinoma

Disease Markers

Volumn 34, Issue 4, 2013, Pages 219-228

  Malaguarnera, Giulia ^a   Paladina, Isabella ^b   Giordano, Maria ^a,b   Malaguarnera, Michele ^c   Bertino, Gaetano ^b   Berretta, Massimiliano ^c  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

CA 19 9; CEA; Cholangiocarcinoma; tumor markers

Indexed keywords

C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; MATRILYSIN; MUCIN; PYRUVATE KINASE; SEROTONIN; SIALIC ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

BILE DUCT CARCINOMA; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER PROGNOSIS; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; HUMAN; LIVER CIRRHOSIS; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 84876231743     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-130964     Document Type: Review

References (127)

1. G.L. Tyson, H.B. El-Serag. Risk factors for cholangiocarcinoma. Hepatology 54 (2011), 173-184.
2. B.R. Blechacz, G.J. Gores. Cholangiocarcinoma. Clin Liver Dis 12 (2008), 131-150. (Pubitemid 351163138)
3. R.A. Standish, E. Cholongitas, A. Dhillon, A.K. Burroughs, A.P. Dhillon. An appraisal of the histopathological assessment of liver fibrosis. Gut 55 (2006), 569-78.
4. O. Nehls, M. Gregor, B. Klump. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 24 (2004), 139-154. (Pubitemid 38738343)
5. S.G. Lee, G.W. Song, S. Hwang, T.Y. Ha, D.B. Moon, et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci 17 (2010), 476-489.
6. S. Hirano, S. Kondo, E. Tanaka, T. Shichinohe, T. Tsuchikawa, et al. Outcome of surgical treatment of hilar cholangiocarcinoma: A special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci 17 (2010), 455-462.
7. V. Cardinale, G. Carpino, L. Reid, E. Gaudio, D. Alvaro. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol 4 (2012), 94-102.
8. M. Yamamoto, S. Ariizumi. Surgical outcomes of intrahepatic cholangiocarcinoma. Surg Today 41 (2011) 896-902.
9. O. Farges, D. Fuks. Clinical presentation and management of intrahepatic cholangiocarcinoma. Gastroenterol Clin Biol 34 (2010), 191-199.
10. S. Yamasaki. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 10 (2003), 288-291. (Pubitemid 37407518)
11. H. Nathan, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 16 (2009), 14-22.
12. A. Sasaki, et al. Intrahepatic peripheral cholangiocarcinoma: Mode of spread and choice of surgical treatment. Br J Surg 85 (1998), 1206-1209. (Pubitemid 28430419)
13. B. Blechacz, G.J. Gores. Positron emission tomography scan for a hepatic mass. Hepatology 52 (2010), 2186-2191.
14. V. Vilgrain, et al. Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr 21 (1997), 59-65. (Pubitemid 27061157)
15. C.U. Corvera, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 206 (2008), 57-65. (Pubitemid 350267250)
16. G. Bertino, A. Ardiri, M. Malaguarnera, G. Malaguarnera, N. Bertino, G.S. Calvagno. Hepatocellualar carcinoma serum markers. Semin Oncol 39 (2012), 410-33.
17. N. Chalasani, A. Baluyut, A. Ismail, A. Zaman, G. Sood, R. Ghalib, T.M. McCashland, K.R. Reddy, X. Zervos, M.A. Anbari, H. Hoen. Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology 31 (2000), 7-11. (Pubitemid 30033681)
18. A.H. Patel, D.M. Harnois, G.G. Klee, N.F. LaRusso, G.J. Gores. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95 (2000), 204-7. (Pubitemid 30041560)
19. C. Levy, J. Lymp, P. Angulo, G.J. Gores, N. Larusso, K.D. Lindor. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 50 (2005), 1734-40. (Pubitemid 41203674)
20. S.A. Khan, H.C. Thomas, B.R. Davidson, S.D. Taylor-Robinson. Cholangiocarcinoma. Lancet 366 (2005), 1303-1314. (Pubitemid 41416587)
21. J.K. Ramage, A. Donaghy, J.M. Farrant, R. Iorns, R. Williams. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108 (1995), 865-9.
22. W.F. Shen, W. Zhong, F. Xu, T. Kan, L. Geng, F. Xie, C.J. Sui, J.M. Yang. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol 15 (2009), 5976-82.
23. L.Y. Tao, L. Cai, X.D. He, W. Liu, Q. Qu. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg 76 (2010), 1210-1213.
24. H. Koprowski, Z. Steplewski, K. Mitchell, M. Herlyn, D. Herlyn, P. Fubrer. Colorectal carcinoma antigens detected by hybridoma antibodies, Somatic Cell. Genet 5 (1979), 957-971. (Pubitemid 10132218)
25. C.X. Zheng, W.H. Zhan, J.Z. Zhao, D. Zheng, D.P. Wang, Y.L. He et al. The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer, World J. Gastroenterol 7 (2001), 431-434. (Pubitemid 32586534)
26. Y. Nakanuma, M. Sasaki. Expression of blood group-related antigens in the intrahepatic biliary tree and hepatocytes in normal livers and various hepatobiliary diseases, Hepatology 10 (1988), 174-178.
27. T. Kanai, S. Hirohashi, M.P. Upton, Y. Ino, Y. Shimosato. Expression of Lewis blood group antigens in cancerous and non-cancerous liver, Japan J. Cancer Res 78 (1987), 968-976. (Pubitemid 17151573)
28. F.H. Li, X.Q. Chen, H.Y. Luo, Y.H. Li, F. Wang, M.Z. Qiu, K.Y. Teng, Z.H. Li, R.H. Xu. Prognosis of 84 intrahepatic cholangiocarcinoma patients]. Ai Zheng 28 (2009), 528-32.
29. S. Miwa, S. Miyagawa, A. Kobayashi, Y. Akahane, T. Nakata, M. Mihara et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery, J. Gastroenterol 41 (2006), 893-900. (Pubitemid 44594231)
30. C.Y. Chen, S.C. Shiesh, H.C. Tsao, X.Z. Lin. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma-the influence of sampling time and hepatolithiasis, Hepatogastroenterology 49 (2002), 616-20.
31. B.W. Yin, K.O. Lloyd. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin. MUC 16. J Biol Chem 276 (2001), 27371-27375.
32. H. Hardardottir, T.H. 2nd Parmley, J.G. Jr Quirk, M.M. Sanders, F.C.Miller, T.J. O'Brien. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obset Gynecol 163 (1990), 1925-1931.
33. H. Kobayashi, H. Ohi, N. Moniwa, H. Shinohara, T. Terao. Characterization of CA125 antigen identified by monoclonal antibodies that recognize different epitopes. Clin Biochem 26 (1993), 391-397. (Pubitemid 23326742)
34. M. Higashi, N. Yamada, S. Yokoyama, S. Kitamoto, K. Tabata, C. Koriyama, S.K. Batra, S. Yonezawa. Pathobiological implications of MUC16/CA 125 expression in intrahepatic cholangiocarcinoma-Mass forming type. Pathobiology 79 (2012), 101-106.
35. M. Uccello, G. Malaguarnera, E.M. Pelligra, A. Biondi, F. Basile, M. Motta. Lipoprotein (a) as a potential marker of residual liver function in hepatocellular carcinoma. Indian J Med Paediatr Oncol 32 (2011), 71-5.
36. H. Berbéc, A. Paszkowska, B. Siwek, K. Gradziel, M. Cybulski. Total serum sialic acid concentration as a supporting marker of malignancy in ovarian neoplasia. Eur J Gynaecol Oncol 20 (1999), 389-92.
37. M. Uccello, G. Malaguarnera, M. Vacante, M. Motta. Serum bone sialoprotein levels and bone metastases. J Cancer Res Ther 7 (2011), 115-9.
38. S. Narayanan. Sialic acid as a tumor marker. Ann Clin Lab Sci 24 (1994), 376-84. (Pubitemid 24203481)
39. G. Malaguarnera, E. Cataudella, M. Giordano, G. Nunnari, G. Chisari, M.Malaguarnera. Toxic hepatitis in occupational exposure to solvents.World J Gastroenterol 18 (2012), 2756-66.
40. S. Wongkham, C. Boonla, S. Kongkham, C. Wongkham, V. Bhudhisawasdi, B. Sripa. Serum total sialic acid in cholangiocarcinoma patients: An ROC curve analysis. Clin Biochem 34 (2001), 537-41. (Pubitemid 34014846)
41. K. Okada, Y. Shimizu, S. Nambu, K. Higuchi, A. Watanabe. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 9 (1994), 462-7. (Pubitemid 24312840)
42. J. Park, L. Tadlock, G.J. Gores, T. Patel. Inhibition of interleukine 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 30 (1999), 1128-33. (Pubitemid 29510848)
43. J.S. Goydos, A.M. Brumfield, E. Frezza, A. Booth, M.T. Lotze, S.E. Carty. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 227 (1998), 398-404. (Pubitemid 28131021)
44. T. Gerhardt, S. Milz, M. Schepke, G. Feldmann, M. Wolff, T. Sauerbruch et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 14 (2006), 5495-500. (Pubitemid 44501808)
45. M. Uccello, G. Malaguarnera, T. Corriere, A. Biondi, F. Basile, M. Malaguarnera. Risk of hepatocellular carcinoma in workers exposed to chemicals. Hepat Mon 12 (2012), e5943.
46. T. Saisho, T. Okusaka, H. Ueno, C. Morizane, S. Okasada. Prognostic factors in patients with advanced biliary tract receiving chemotherapy. Hepatogastroenterology 52 (2005), 1654-1658. (Pubitemid 41745604)
47. R. Moll, W.W. Franke, D.L. Schiller et al. The catalogue oh human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 31 (1982), 11-24. (Pubitemid 13215192)
48. R. Moll, D.L. Schiller, W.W. Franke et al. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol 111 (1990), 567-580.
49. J.M. Bréchot, S. Chevret, J. Nataf, C. Le Gall, J. Frétault, J. Rochemaure et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: A prospective study of 116 patients. Eur J Cancer 33 (1997), 385-91. (Pubitemid 27168063)
50. M. Takada, N. Masuda, E. Matsuura, Y. Kusunoki, K. Matui, K. Nakagawa et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer 71 (1995), 160-5.
51. T. Uenishi, S. Kubo, T. Yamamoto, T. Shuto, M. Ogawa, H. Tanaka et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence, Cancer Sci. 94 (2003), 851-7. (Pubitemid 37406966)
52. J.L. Pujol, O. Molinier, W. Ebert, J.P. Daurès, F. Barlesi, G. Buccheri et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: Results of a meta-analysis in 2063 patients. Br J Cancer 90 (2004), 2097-105. (Pubitemid 38869712)
53. I. Doweck, M. Barak, N. Uri, E. Greenberg. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 83 (2000), 1696-701. (Pubitemid 32001716)
54. B. Nakata, T. Takashima, Y. Ogawa, T. Ishikawa, K. Hirakawa. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer 31 (2004), 873-8. (Pubitemid 39273778)
55. Y. Kawarada, R. Mizumoto. Cholangiocellular carcinoma of the liver. Am J Surg 147 (1984), 354-9. (Pubitemid 14154585)
56. Y. Kawarada, R. Mizumoto. Diagnosis and treatment of cholangiocellular carcinoma of the liver. Hepatogastroenterology 37 (1990), 176-81.
57. N. Yamanaka, E. Okamoto, T. Ando et al. Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinoma. Cancer 76 (1995), 2449-56.
58. K.M. Chu, E.C. Lai, S. Al-Hadeedi, et al. Intrahepatic cholangiocarcinoma. World J Surg 21 (1997), 301-6. (Pubitemid 27100493)
59. H.J. Kim, S.S. Yun,N. K.H. Jung et al. Intrahepatic cholangiocarcinoma in Korea. J Hep Bil Pancr Surg 6 (1999), 142-8.
60. T. Uenishi, K. Hirohashi, S. Kubo, et al. Clinicopathologic factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg 88 (2001), 969-74. (Pubitemid 34015579)
61. T. Uenishi et al. Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer. 88 (2003), 1894-1899. (Pubitemid 36833248)
62. T. Uenishi et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 15 (2008), 583-589. (Pubitemid 351643031)
63. P. Van Eyken, V.J. Desmet. Cytokeratins and the liver, Liver 13 (1993), 113-122. (Pubitemid 23228705)
64. A. Sanchez-Capelo, Dual role for TGF-beta1 in apoptosis. Cytokine Growth Factor Rev 16 (2005), 15-34.
65. N. Fausto, J.E. Mead, P.A. Gruppuso, L. Brown. TGF-beta in liver development, regeneration and carcinogenesis. Ann N Y Acad Sci 593 (1991), 231-242.
66. G. Malaguarnera, M. Giordano, I. Paladina, M. Berretta, A. Cappellani, M. Malaguarnera. Serum markers of hepatocellular carcinoma. Dig Dis Sci 55 (2010), 2744-55.
67. Y. Yata, P. Gotwals, V. Koteliansky, D.C. Rockey, Dosedependent inhibition of hepatic fibrosis in mice by a TGFbeta soluble receptor: Implications for antifibrotic therapy. Hepatology 35 (2002), 1022-1030. (Pubitemid 34453999)
68. C.B. Thompson. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995), 1456-1462.
69. L.A. Saperstein, R.L. Jirtle, M. Farouk, H.J. Thompson, K.S. Chung,W.C. Meyers. Transforming growth factor-beta 1 and mannose 6-phosphate/insulin-like growth factor-II receptor expression during intrahepatic bile duct hyperplasia and biliary fibrosis in the rat. Hepatology 19 (1994), 412-417. (Pubitemid 24046786)
70. S. Takiya, T. Tagaya, K. Takahashi, H. Kawashima, M. Kamiya, Y. Fukuzawa, S. Kobayashi, A. Fukatsu, K. Katoh, S. Kakumu. Role of transforming growth factor beta 1 on hepatic regeneration and apoptosis in liver diseases. J Clin Pathol 48 (1995), 1093-1097. (Pubitemid 26014847)
71. Y. Zen, K. Harada, M. Sasaki, T. Chen, M. Chen, T. Yeh et al. Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta1 by overexpression of cyclin D1. Lab Invest 85 (2005), 572-581. (Pubitemid 40523947)
72. S. Yokomuro, H. Tsuji, J.G. 3rd Lunz, T. Sakamoto, T. Ezure, N. Murase et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: Comparison of a cholangiocarcinoma cell line with primary cultures of nonneoplastic biliary epithelial cells. Hepatology 32 (2000), 26-35. (Pubitemid 30432362)
73. T. Shimizu, S. Yokomuro, Y. Mizuguchi, Y. Kawahigashi, Y. Arima, N. Taniai et al. Effect of transforming growth factor-β1 on human intrahepatic cholangiocarcinoma cell growth. World J Gastroenterol 12 (2006), 6316-24. (Pubitemid 44712413)
74. L. Malaguarnera, E. Cristaldi, M. Malaguarnera. The role of immunity in elderly cancer. Crit Rev Oncol Hematol 74 (2010), 40-60.
75. Y. Sato, K. Harada, K. Itatsu, H. Ikeda, Y. Kakuda, S. Shimomura, X. Shan Ren, N. Yoneda, M. Sasaki, Y. Nakanuma. Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am J Pathol 177 (2010), 141-52.
76. L.J. Deftos. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 12 (1991), 181-7.
77. A. Spadaro, A. Ajello, C.Morace, A. Zirilli, G. D'Arrigo, C. Luigiano et al. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol 11 (2005), 1987-90. (Pubitemid 40520997)
78. M. Malaguarnera, M. Vacante, R. Fichera, A. Cappellani, E. Cristaldi, M. Motta. Chromogranin A serum levels as a marker of progression in hepatocellular carcinoma (HCC) of elderly patients. Arch Gerontol Geriatr 2009.
79. M.C. Zatelli, M. Torta, A. Leon, M.R. Ambrosio, M. Gion, P. Tomassetti et al. Chromogranin as a marker of neuroendocrine neoplasia: An Italian Multicenter study. Endocr Relat Cancer 14 (2007), 473-82. (Pubitemid 47242645)
80. Y. Nakanuma. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas? Pathol Int 60 (2010), 419-429.
81. Y. Nakanuma, M. Sasaki, Y. Sato, X. Ren, H. Ikeda, K. Harada. Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. World J Hepatol 1 (2009), 35-42.
82. Y. Nakanuma, Y. Sato, K. Harada, M. Sasaki, J. Xu, H. Ikeda. Pathological classification of intrahepatic cholangiocarcinoma based on a new conceptWorld J Hepatol 2 (2010), 419-427.
83. L.A. Erickson, R.V. Lloyd. Practical markers used in the diagnosis of endocrine tumors. Adv Anat Pathol 11 (2004), 175-89.
84. G.M. Oremek, S. Teigelkamp, W. Kramer, E. Eigenbrodt, K.H. Usadel. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 19 (1999), 2599-601. (Pubitemid 29392419)
85. P.D. Hardt, B.K. Ngoumou, J. Rupp, H. Schnell-Kretschmer, H.U. Kloer. Tumor M2-pyruvate kinase: A promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 20 (2000), 4965-8. (Pubitemid 32319060)
86. G. Schulze, The tumor marker tumorM2-PK: An application in the diagnosis of gastrointestinal cancer. Anticancer Res 20 (2000), 4961-4. (Pubitemid 32319059)
87. J. Schneider, H. Morr, H.G. Velcovsky, G. Weisse, E. Eigenbrodt. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 24 (2000), 531-5. (Pubitemid 32099839)
88. E. Eigenbrodt, M. Reinacher, U. Scheefers-Borchel, H. Scheefers, R. Friis. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncogenesis 3 (1992), 91-115.
89. M. Malaguarnera, C. Risino, M.P. Gargante, G. Oreste, G. Barone, A.V. Tomasello, M. Costanzo, M.A. Cannizzaro. Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J Gastroenterol 12 (2006), 4541-5. (Pubitemid 44256342)
90. E. Vinci, E. Rampello, L. Zanoli, G. Oreste, G. Pistone, M. Malaguarnera. Serum carnitine levels in patients with tumoral cachexia. Eur J Intern Med 16 (2005), 419-23. (Pubitemid 41405711)
91. U. Brinck, E. Eigenbrodt, M. Oehmke, S. Mazurek, G. Fischer. L-and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch 424 (1994), 177-185.
92. P. Steinberg, A. Klingelhöffer, A. Schäfer, G. Wüst, G. Weisse, F. Oesch et al. Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrososmorpholine-treated rats. Virchows Arch 434 (1999), 213-220. (Pubitemid 29186805)
93. H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, R.Wei et al. TheM2 slice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452 (2008), 230-233. (Pubitemid 351380249)
94. E. Eigenbrodt, F. Kallinowski, M. Ott, S. Mazurek, P. Vaupel. Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res 18 (1998), 3267-74. (Pubitemid 28546445)
95. Y.G. Li, N. Zhang. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma. Dig Liver Dis 41 (2009), 605-8.
96. M. Verma. Carcinoma associated mucins molecular biology and clinical application, Cancer Biochem. Biophys 14 (1994), 151-62.
97. S.J. Gendler, A.P. Spicer. Epithelial mucin genes. Annu Rev Physiol 57 (1995), 607-34.
98. S.K. Chang, A.F. Dohrman, C.B. Basbaum, S.B. Ho, T. Tsuda, N.W. Toribara et al. Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer. Gastroenterology 107 (1994), 28-36. (Pubitemid 24195342)
99. M.P. Buisine, L. Devisme, V. Maunorv, E. Deschodt, B. Gosselin, M.C. Copin et al. Developmental mucin gene expression in the gastroduodenal tract and accessory digestive glands. I. Stomach. A relationship to gastric carcinoma. J Histochem Cytochem 481 (2000), 657-66.
100. S.B. HO, G.A. Niehans, C. Lyftogt, P.S. Yan, D.L. Cherwitz, E.T. Gum et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53 (1993), 641-51. (Pubitemid 23059449)
101. V.P. Bhavanandan. Cancer-associated mucins and mucintype glycoproteins. Glycobiology 1 (1991), 493-503.
102. M. Sasaki, Y. Nakanuma, T. Terada, Y.S. Kim. Biliary epithelial expression of MUC1, MUC2, MUC3 and MUC5/6 apomucins during intrahepatic bile duct development and maturation. An immunohistochemical study. Am J Pathol 147 (1995), 574-579.
103. M. Sasaki, Y. Nakanuma. Expression of mucin core protein of mammary type in primary liver cancer. Hepatology 20 (1994), 1192-1197. (Pubitemid 24323565)
104. K. Yamashita, S. Yonezawa, S. Tanaka, H. Shirahama, K. Sakoda, K. Imai, P.X. Xing, I.F. McKenzie, J. Hilkens, Y.S. Kim. Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma. Int J Cancer 55 (1993), 82-91. (Pubitemid 23261711)
105. M. Sasaki, Y. Nakanuma, Y.S. Kim. Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: An immunohistochemical study. Hepatology 24 (1996), 1074-1078. (Pubitemid 26365906)
106. N. Matsumura, M. Yamamoto, A. Aruga, K. Takasaki, M. Nakano. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangio-carcinoma. Cancer 94 (2002), 1770-1776. (Pubitemid 34241116)
107. C. Boonla, B. Sripa, P. Thuwajit, U. Cha-On, A. Puapairoj, M. Miwa, S. Wongkham. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol 11 (2005), 4939-4946. (Pubitemid 41227189)
108. T.S.Yeh, J.H. Tseng, T.C. Chen, N.J. Liu, C.T. Chiu, Y.Y. Jan et al. Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions. Hepatology 42 (2005), 657-64.
109. S.M. Zhao, X.Z. Zhu, Y. Ji, J. Hou. Expression of mucin glycoproteins and cytokeratins in intrahepatic cholangiocarcinoma. Zhonghua Bing Li Xue Za Zhi 37 (2008), 749-53.
110. L.J. McCawley, L.M. Matrisian. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today 6 (2000), 149-56. (Pubitemid 30171365)
111. A.R. Folgueras, A.M. Pendás, L.M. Sánchez, C. López-Otín. Matrix metalloproteinases in cancer: From new functions to improved inhibition strategies. Int J Dev Biol 48 (2004), 411-24. (Pubitemid 39360392)
112. A. Acar, A. Onan, U. Coskun, A. Uner, U. Bagriacik, F. Atalay et al. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer. Med Oncol 25 (2008), 279-83.
113. G. Sarkissian, P. Fergelot, P.Y. Lamy, J.J. Patard, S. Culine, P. Jouin et al. Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem 54 (2008), 574-81. (Pubitemid 351348152)
114. K. Itatsu, Y. Zen, S. Ohira, A. Ishikawa, Y. Sato, K. Harada et al. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int 27 (2007), 1174-84. (Pubitemid 47543145)
115. M. Diksic, S.N. Young. Study of the brain serotonergic system with labeled alpha-methyl-L-tryptophan. J Neurochem 78 (2001), 1185-1200. (Pubitemid 32899751)
116. M.M. Costedio, N. Hyman, G.M. Mawe. Serotonin and its role in colonic function and in gastrointestinal disorders. Dis Colon Rectum 50 (2007), 376-388. (Pubitemid 46394454)
117. G.K. Papadimas, K.N. Tzirogiannis, G.I. Panoutsopoulos, M.D. Demonakou, S.D. Skaltsas, R.I. Hereti et al. Effect of serotonin receptor 2 blockage on liver regeneration after partial hepatectomy in the rat liver, Liver Int 26 (2006), 352-361. (Pubitemid 43349327)
118. R. Acquaviva, L. Iauk, V. Sorrenti, R. Lanteri, R. Santangelo, A. Licata, F. Licata, A. Vanella, M. Malaguarnera, S. Ragusa, C. Di Giacomo. Oxidative profile in patients with colon cancer: Effects of Ruta chalepensis L. Eur Rev Med Pharmacol Sci 15 (2011), 181-91.
119. L. Proietti, R. Fantauzzo, B. Longo, M. Malaguarnera, M. Trizzino, D. Duscio. Viral hepatitis B among the health care workers. Experience at a health facility in Eastern Sicily. Recenti Prog Med 95 (2004), 196-9. (Pubitemid 38508953)
120. M.G. Swain, M. Maric. Improvement in cholestasisassociated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 25 (1997), 291-4. (Pubitemid 27069044)
121. M. Marzioni, S. Glaser, H. Francis et al. Autocrine/paracrine regulation of the growth of the biliarytree by the neuroendocrine hormone serotonin. Gastroenterology 128 (2005), 121-37. (Pubitemid 40039964)
122. G. Alpini, P. Invernizzi, E. Gaudio, J. Venter, S. Kopriva, F. Bernuzzi, P. Onori, A. Franchitto, M. Coufal, G. Frampton, D. Alvaro, S.P. Lee, M. Marzioni, A. Benedetti, S. DeMorrow. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res 68 (2008), 9184-93.
123. K. Shirabe, M. Shimada, N. Harimoto, K. Sugimachi, Y. Yamashita, E. Tsujita et al. Intrahepatic cholangiocarcinoma: Its mode of spreading and therapeutic modalities. Surgery 131 (2002), S159-64.
124. H. Minato, Y. Nakanuma, T. Terada. Expression of blood group related antigens in cholangiocarcinoma in relation to non neoplastic bile ducts. Histopathology 28 (1996), 411-419. (Pubitemid 26157688)
125. E. Bjornsson, A. Kilander, R. Olsson. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary scelorising cholangitis. Liver 19 (1999), 501-508. (Pubitemid 30019064)
126. C.L. Lin, C.S. Changchien, Y.S. Chen. Mirizzi's syndrome with a high CA 19-9 level mimicking cholangiocarcinoma. Am J Gastroenterol 92 (1997), 2309-2310.
127. Y. Horsmans, A. Laka, B.E. van Beers, C. Descamps, J.F. Gigot, A.P. Geubel. Hepatobiliary cystadenocarcinoma without ovarian stroma and normal CA 19-9 levels. Unusually prolonged evolution. Dig Dis Sci 42 (1997), 1406-1408. (Pubitemid 27339354)